Physician profile
Audwin Nelson
NPI 1467453126
$4,859.36
in general payments reported to CMS, 2019-2025
30 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $304 · 2022: $172 · 2023: $677 · 2024: $1,697 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Travel and Lodging: $1,125 · Education: $31.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.72 |
| Travel and Lodging | $1,125.18 |
| Education | $31.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,704.40 | 2022-2025 | Minimed 780g |
| Novo Nordisk INC | $523.33 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $456.15 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $269.36 | 2023-2025 | |
| Exact Sciences Corporation | $208.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $206.48 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $171.60 | 2019-2025 | Otezla, Repatha, Repatha |
| Cequr Corporation | $149.87 | 2023 | Cequr Simplicity |
| Abbott Laboratories | $139.55 | 2023-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $89.94 | 2019-2023 | Verquvo, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $86.13 | 2019-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $82.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $82.82 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $69.05 | 2024 | Nuzyra |
| Pfizer INC. | $67.30 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.36 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.72 | 2023-2025 | Ofev, Jardiance, Jascayd |
| Dexcom, INC. | $61.11 | 2022-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $58.53 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $54.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.56 | 2022-2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $34.87 | 2023 | Shingrix |
| Axsome Therapeutics, INC. | $34.85 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $27.86 | 2023 | Rexulti |
| Amarin Pharma, INC. | $27.19 | 2019 | |
| Lundbeck LLC | $26.32 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.49 | 2020 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audwin Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.